The SOLAR-1 study was a phase III randomized trial investigating the efficacy of the α-selective PI3K inhibitor and degrader alpelisib (BYL719; Novartis Pharma AG) plus fulvestrant in patients with HR+/HER2− advanced breast cancer who had received prior ET [2,13,14]. The gene discussed is PIK3CA; the disease is breast carcinoma.